Ranivue Injection contains the active ingredient Ranibizumab. It is an anti-neovascularisation agent in the class of medications called vascular endothelial growth factor A (VEGF-A) antagonists. It is used in adults to treat several eye diseases causing vision impairment. It is used to treat wet age-related macular degeneration (AMD, a persistent eye disease that causes loss of the ability to see straight ahead and may make it more difficult to read, drive, or perform other daily activities). Ranivue Injection is also used to treat myopic choroidal neovascularisation (mCNV; a complication in near-sighted people where new blood vessels can grow in the back of the eye), and to treat macular edema after retinal vein occlusion (an eye disease caused by blockage of blood flow from the eye that leads to blurry vision and vision loss). It is also used to treat diabetic macular edema (an eye disease caused by diabetes that can lead to vision loss) and diabetic retinopathy (damage to the eyes caused by diabetes). Do not use Ranivue Injection if you are allergic to Ranibizumab or other ingredients of this medicine. Do not take this medicine if you have an infection in or around your eye and if you have pain or redness in your eye. Inform your doctor immediately if you develop symptoms such as eye pain or increased discomfort, worsening eye redness, blurred or decreased vision, an increased number of small particles in your vision, or increased sensitivity to light. Inform your doctor if you have a prior history of eye conditions or eye treatments or had a stroke before initiating the treatment.